Wall Street analysts forecast that K2M Group Holdings Inc (NASDAQ:KTWO) will post earnings of ($0.16) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for K2M Group’s earnings, with the lowest EPS estimate coming in at ($0.21) and the highest estimate coming in at ($0.10). K2M Group posted earnings per share of ($0.20) during the same quarter last year, which indicates a positive year-over-year growth rate of 20%. The business is expected to report its next quarterly earnings report on Wednesday, November 7th.
On average, analysts expect that K2M Group will report full year earnings of ($0.77) per share for the current fiscal year, with EPS estimates ranging from ($0.84) to ($0.68). For the next financial year, analysts anticipate that the firm will post earnings of ($0.57) per share, with EPS estimates ranging from ($0.70) to ($0.47). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for K2M Group.
K2M Group (NASDAQ:KTWO) last announced its quarterly earnings data on Wednesday, August 1st. The medical device company reported ($0.25) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.06). The company had revenue of $73.58 million for the quarter, compared to analysts’ expectations of $70.85 million. K2M Group had a negative return on equity of 16.27% and a negative net margin of 14.49%. The company’s revenue was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.21) earnings per share.
Shares of KTWO stock traded down $0.03 during trading hours on Wednesday, hitting $27.25. 1,152,400 shares of the company were exchanged, compared to its average volume of 468,627. The firm has a market cap of $1.19 billion, a P/E ratio of -31.39 and a beta of 1.61. K2M Group has a 1 year low of $16.44 and a 1 year high of $27.50. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.48 and a quick ratio of 2.13.
In related news, CFO Gregory S. Cole sold 1,480 shares of the stock in a transaction that occurred on Thursday, August 16th. The shares were sold at an average price of $20.08, for a total transaction of $29,718.40. Following the completion of the sale, the chief financial officer now owns 65,659 shares of the company’s stock, valued at approximately $1,318,432.72. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Gregory S. Cole sold 82,304 shares of the stock in a transaction that occurred on Thursday, August 30th. The stock was sold at an average price of $27.40, for a total transaction of $2,255,129.60. Following the sale, the chief financial officer now directly owns 147,963 shares of the company’s stock, valued at approximately $4,054,186.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 85,346 shares of company stock valued at $2,318,362. Corporate insiders own 6.00% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers increased its position in K2M Group by 7.4% during the 2nd quarter. Rhumbline Advisers now owns 39,058 shares of the medical device company’s stock worth $879,000 after purchasing an additional 2,682 shares in the last quarter. Northern Trust Corp increased its position in K2M Group by 0.5% during the 1st quarter. Northern Trust Corp now owns 549,513 shares of the medical device company’s stock worth $10,413,000 after purchasing an additional 2,756 shares in the last quarter. Oppenheimer Asset Management Inc. increased its position in K2M Group by 18.0% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 19,285 shares of the medical device company’s stock worth $366,000 after purchasing an additional 2,942 shares in the last quarter. Suntrust Banks Inc. increased its position in K2M Group by 5.1% during the 1st quarter. Suntrust Banks Inc. now owns 64,608 shares of the medical device company’s stock worth $1,223,000 after purchasing an additional 3,126 shares in the last quarter. Finally, Teton Advisors Inc. increased its position in K2M Group by 10.0% during the 1st quarter. Teton Advisors Inc. now owns 44,000 shares of the medical device company’s stock worth $834,000 after purchasing an additional 4,000 shares in the last quarter.
K2M Group Company Profile
K2M Group Holdings, Inc, a medical device company, provides spine and minimally invasive solutions in the United States and internationally. The company offers implants, disposables, and instruments primarily to hospitals for use by spine surgeons to treat spinal pathologies, such as deformity, trauma, and tumor.
Read More: Closed-End Mutual Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for K2M Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group and related companies with MarketBeat.com's FREE daily email newsletter.